NCT06451614 2026-04-16
HYDROSPACE
Boston Scientific Corporation
Phase NA Active not recruiting
Clinical Trials
1,287 trialsNCT06780670 2026-04-16
PSMAcTION
Novartis
Phase 2/3 Recruiting
NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT04905069 2026-04-15
SABRE
Boston Scientific Corporation
Phase NA Active not recruiting
NCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06511141 2026-04-15
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Axonics, Inc.
Phase NA Recruiting
NCT07236112 2026-04-15
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
C Ray Therapeutics
Phase 1 Active not recruiting
NCT04122976 2026-04-14
DAROL
Bayer
Active not recruiting
NCT05847166 2026-04-14
A Phase 2/3,PSMA-T4, Prostate Cancer
NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom
Phase NA Recruiting
NCT06122584 2026-04-14
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
ABX advanced biochemical compounds GmbH
Phase 3 Recruiting
NCT07529717 2026-04-14
CRIUS-1
AstraZeneca
Phase 1/2 Not yet recruiting
NCT01946204 2026-04-13
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02123758 2026-04-13
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT02257736 2026-04-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02531516 2026-04-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT03523442 2026-04-13
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03767244 2026-04-13
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108208 2026-04-13
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT04557059 2026-04-13
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT04577833 2026-04-13
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04644770 2026-04-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04662580 2026-04-13
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04898634 2026-04-13
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05413850 2026-04-13
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT05683691 2026-04-13
VAPOR 2
Francis Medical Inc.
Phase NA Active not recruiting
NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
NCT06190899 2026-04-13
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT06238479 2026-04-13
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06517719 2026-04-13
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Novartis
Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT06925737 2026-04-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07082920 2026-04-13
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07319871 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07451002 2026-04-13
OBSAPA
Janssen Cilag S.A.S.
Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06056830 2026-04-09
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06801236 2026-04-09
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics Limited
Phase 1 Recruiting
NCT06970847 2026-04-09
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT07406282 2026-04-09
Double-DARE
Bayer
Recruiting
NCT05467176 2026-04-08
OPTYX
Sumitomo Pharma America, Inc.
Active not recruiting
NCT06235151 2026-04-08
Solar-Stage
Curium US LLC
Phase 3 Recruiting
NCT07047118 2026-04-08
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT07181161 2026-04-08
SEACLIFF
AstraZeneca
Phase 1/2 Recruiting
NCT07517198 2026-04-08
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase 1 Recruiting
NCT04821622 2026-04-07
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
NCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT07214961 2026-04-07
ARTISAN
ARTBIO Inc.
Phase 1 Active not recruiting